Valuation: Glaukos Corporation

Market Cap 9.1B 7.99B 7.55B 6.88B 12.87B 873B 12.96B 90.29B 34.97B 446B 34.18B 33.44B 1,433B P/E 2026 *
-191x
P/E 2027 * 519x
Enterprise Value 8.93B 7.84B 7.4B 6.74B 12.62B 856B 12.71B 88.56B 34.3B 437B 33.53B 32.8B 1,405B EV / Sales 2026 *
12.9x
EV / Sales 2027 * 10.4x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -
1 day-0.29%
1 week-5.73%
Current month-14.00%
1 month-14.86%
3 months+8.32%
6 months+40.90%
Current year+36.77%
1 week 151.01
Extreme 151.01
166.74
1 month 151.01
Extreme 151.01
185.35
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Sell

Executive/Senior Manager

-1,457 0.0025%
28/08/26 Sell

Executive/Senior Manager

-13,744 0.0240%
19/08/26 Exercice

Director

7,500 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%-5.73%+89.55%+102.21% 9.1B
+0.97%-1.00%-26.10%-5.23% 104B
+0.35%-1.90%-23.58%-3.12% 11.23B
-1.29%+3.12%-49.04%-67.22% 4.14B
-0.91%+6.44%-25.51%+26.97% 2.49B
+2.46%-8.18%-8.82%-61.91% 2.04B
-3.28%+0.48% - - 1.94B
-1.43%+0.29%-24.06%-32.26% 1.53B
-3.06%-2.00%-34.09%-47.46% 1.46B
Average -0.72%-0.94%-12.71%-11.00% 15.38B
Weighted average by Cap. +0.63%-1.21%-18.67%-0.78%

Financials

2026 *2027 *
Net sales 691M 606M 573M 522M 977M 66.23B 984M 6.85B 2.65B 33.84B 2.59B 2.54B 109B 847M 743M 702M 639M 1.2B 81.14B 1.21B 8.4B 3.25B 41.45B 3.18B 3.11B 133B
Net income -51.87M -45.51M -42.99M -39.17M -73.33M -4.97B -73.86M -514M -199M -2.54B -195M -191M -8.16B 19.14M 16.8M 15.86M 14.46M 27.06M 1.83B 27.25M 190M 73.52M 937M 71.86M 70.31M 3.01B
Net Debt -175M -153M -145M -132M -247M -16.76B -249M -1.73B -672M -8.56B -657M -642M -27.52B -273M -239M -226M -206M -386M -26.15B -388M -2.71B -1.05B -13.36B -1.02B -1B -42.94B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
25/09/26 US$154.43 -0.29% 826,237
24/09/26 US$154.88 +0.91% 838,399
23/09/26 US$153.49 -3.98% 1,026,755
22/09/26 US$159.86 -1.03% 1,102,409
21/09/26 US$161.53 -1.39% 806,468
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
154.43USD
Average target price
198.69USD
Spread / Average Target
+28.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock